Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Ribociclib

    Virtual Booth

    Contact Supplier

    Ribociclib

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Ribociclib Succinate

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Ribociclib Succinate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 8,594Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novartis' Kisqali Keeps 1 in 4 Patients Progression-Free
    Novartis' Kisqali Keeps 1 in 4 Patients Progression-Free

    09 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/09/3202238/0/en/1-in-4-metastatic-breast-cancer-patients-treated-with-Novartis-Kisqali-remain-progression-free-beyond-4-years.html

    GLOBENEWSWIRE
    09 Dec 2025
    Share Share
    BBOT Unveils Posters At San Antonio Breast Cancer Symposium
    BBOT Unveils Posters At San Antonio Breast Cancer Symposium

    30 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/30/3178024/0/en/BBOT-Announces-Poster-Presentations-at-the-San-Antonio-Breast-Cancer-Symposium-SABCS.html

    GLOBENEWSWIRE
    30 Oct 2025
    Share Share
    Olema to Present Ph3 OPERA-02 Trial of Palazestrant at SABCS 2025
    Olema to Present Ph3 OPERA-02 Trial of Palazestrant at SABCS 2025

    30 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/30/3177971/0/en/Olema-Oncology-to-Present-Trial-in-Progress-Poster-for-Phase-3-OPERA-02-Trial-of-Palazestrant-Plus-Ribociclib-at-SABCS-2025.html

    GLOBENEWSWIRE
    30 Oct 2025
    Share Share
    Olema Oncology Unveils Phase 1B/2 Palazestrant + Ribociclib Data
    Olema Oncology Unveils Phase 1B/2 Palazestrant + Ribociclib Data

    18 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/18/3168941/0/en/Olema-Oncology-Announces-New-Data-from-the-Phase-1b-2-Trial-of-Palazestrant-Plus-Ribociclib-in-ER-HER2-Metastatic-Breast-Cancer-at-ESMO-2025.html

    GLOBENEWSWIRE
    18 Oct 2025
    Share Share
    Novartis Kisqali Cut Recurrence Risk in Young Early Breast Cancer
    Novartis Kisqali Cut Recurrence Risk in Young Early Breast Cancer

    01 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/01/3091466/0/en/Novartis-Kisqali-reduces-risk-of-recurrence-in-younger-patients-with-early-breast-cancer-in-NATALEE-subgroup-analysis.html

    GLOBENEWSWIRE
    01 Jun 2025
    Share Share
    Targeting Breast Cancer with Ribociclib, Leading CDK 4/6 Inhibitor
    Targeting Breast Cancer with Ribociclib, Leading CDK 4/6 Inhibitor

    28 Mar 2025

    // PRESS RELEASE

    https://www.suanfarma.com/apis-3/targeting-breast-cancer-with-precision-ribociclib-succinate-a-leading-cdk-4-6-inhibitor/

    PRESS RELEASE
    28 Mar 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.